Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Kanglin Biotechnology (Hangzhou) Co. Ltd. operates a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action associated with this portfolio. This figure represents the total volume of outstanding responses required by the patent office at this time.
The portfolio's prosecution involves 1 distinct art unit and 1 distinct examiner. Because the 1 pending office action is handled by a single examiner, the company's current patenting activities are confined to a very specific regulatory channel. This concentration simplifies the logistical oversight of the portfolio's intellectual property assets.
MCCORMICK, CATHERINE LYNN is the busiest examiner for the portfolio, holding 1 busiest examiner pending office action. This examiner is responsible for the entirety of the company's pending workload. Prosecution success for the current assets depends on addressing the specific concerns raised by this examiner within the 1 distinct art unit identified.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCCORMICK, CATHERINE LYNN | 1 | 52.3% | +39.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18022001 | NUCLEIC ACID CONSTRUCT FOR INCREASING ADENO-ASSOCIATED VIRUS YIELD, AND CONSTRUCTION METHOD THEREFOR | MCCORMICK, CATHERINE LYNN | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18022001 | NUCLEIC ACID CONSTRUCT FOR INCREASING ADENO-ASSOCIATED VIRUS YIELD, AND CONSTRUCTION METHOD THEREFOR | MCCORMICK, CATHERINE LYNN | 1638 | §103 | Final Rejection | — | Pending | Mar 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKanglin Biotechnology (Hangzhou) Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Catherine Lynn Mccormick has the most, with 1 of Kanglin Biotechnology (Hangzhou) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
